Valuation: Novavax, Inc.

Market Cap 1.78B 1.57B 1.49B 1.34B 2.53B 171B 2.56B 17.8B 6.85B 87.4B 6.7B 6.55B 280B P/E 2026 *
-17.3x
P/E 2027 * -48.2x
Enterprise Value 2B 1.76B 1.67B 1.51B 2.84B 192B 2.88B 19.99B 7.69B 98.14B 7.52B 7.35B 315B EV / Sales 2026 *
5.37x
EV / Sales 2027 * 7.84x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-12.33%+1,148.37% - - 1.78B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-1.89%-4.00%+29.55%+36.17% 44.25B
+2.58%+4.69%+356.26%+699.54% 43.99B
-1.06%+0.83%+8.29%+103.33% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.18%-9.67%-25.45%+332.79% 24.93B
Average -0.68%+1.97%+55.34%+161.51% 44.09B
Weighted average by Cap. +0.69%+1.83%+59.61%+152.76%

Financials

2026 *2027 *
Net sales 373M 328M 311M 281M 529M 35.76B 536M 3.72B 1.43B 18.28B 1.4B 1.37B 58.61B 266M 234M 222M 200M 378M 25.52B 383M 2.66B 1.02B 13.05B 999M 978M 41.83B
Net income -108M -94.7M -89.73M -81.01M -153M -10.31B -155M -1.07B -413M -5.27B -404M -395M -16.9B -37.93M -33.4M -31.64M -28.57M -53.84M -3.64B -54.54M -379M -146M -1.86B -142M -139M -5.96B
Net Debt 219M 193M 183M 165M 311M 21B 315M 2.19B 841M 10.73B 822M 804M 34.42B 303M 267M 253M 228M 430M 29.07B 436M 3.03B 1.16B 14.86B 1.14B 1.11B 47.65B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-